This company has been marked as potentially delisted and may not be actively trading. NASDAQ:ONS Oncobiologics (ONS) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock Analysis About Oncobiologics Stock (NASDAQ:ONS) Get Oncobiologics alerts:Sign Up Key Stats Today's Range$0.21▼$0.2950-Day Range$0.72▼$7.4052-Week Range$0.57▼$1.53Volume17.52 million shsAverage Volume69,024 shsMarket Capitalization$18.06 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Outlook Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the identification, development, manufacture, and commercialization of ONS-5010/LYTENAVA as the first FDA-approved ophthalmic formulation of bevacizumab-vikg for use in retinal indications, including wet AMD, DME and BRVO. The company was founded by Pankaj Mohan on January 5, 2010 and is headquartered in Iselin, NJ. Read More Receive ONS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Oncobiologics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ONS Stock News HeadlinesBBC slammed for 'biased' Wimbledon coverage of Marketa Vondrousova vs Ons Jabeur finalAugust 2, 2023 | mirror.co.ukMOns Jabeur ‘kicked off’ Wimbledon centre court moments before women’s finalJuly 30, 2023 | mirror.co.ukMTrump’s Plan To Cheat HistoryChina has slashed its U.S. Treasury holdings by more than 45% from their peak, while building gold vaults and payment networks that bypass the dollar entirely. Since the Federal Reserve opened in 1913, the dollar has lost most of its purchasing power. Porter Stansberry argues a new monetary order is forming around AI infrastructure, chips and energy, pointing to stocks like Vertiv, GE Vernova and Arista Networks that have surged hundreds of percent in recent years. | Porter & Company (Ad)Are Away Carry-Ons Worth the Hype?April 27, 2023 | nytimes.comONS - the Office of National StatisticsOctober 5, 2022 | dailymail.co.ukSee More Headlines ONS Stock Analysis - Frequently Asked Questions When did Oncobiologics IPO? Oncobiologics (ONS) raised $35 million in an initial public offering on Friday, May 13th 2016. The company issued 5,800,000 shares at a price of $6.00 per share. Jefferies and Barclays acted as the underwriters for the IPO and Cantor Fitzgerald & Co. was co-manager. What other stocks do shareholders of Oncobiologics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Oncobiologics investors own include Neuralstem (CUR), Exelixis (EXEL), Halozyme Therapeutics (HALO), Prothena (PRTA), LINE (LN), Qiagen (QGEN) and Anavex Life Sciences (AVXL). Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:ONS Previous SymbolNYSE:ONS CIK1649989 Webwww.oncobiologics.com Phone(609) 619-3990FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$38.84 million Net Margins-464.47% Pretax MarginN/A Return on EquityN/A Return on Assets-93.28% Debt Debt-to-Equity RatioN/A Current Ratio0.41 Quick Ratio0.41 Sales & Book Value Annual Sales$3.81 million Price / Sales4.74 Cash FlowN/A Price / Cash FlowN/A Book Value($1.36) per share Price / Book-0.18Miscellaneous Outstanding Shares72,200,000Free FloatN/AMarket Cap$18.06 million OptionableNot Optionable Beta-0.27 The 7 Best High-Yield Dividend Stocks for 2027Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.Get This Free Report This page (NASDAQ:ONS) was last updated on 4/8/2026 by MarketBeat.com Staff. From Our PartnersExecutive Order 14241 Unleashes Trump’s New DollarA landmark executive order, 14241, is reportedly set to reshape how Americans use money starting this December...Porter & Company | SponsoredFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American financial crashes over his 55-year career leadin...Weiss Ratings | SponsoredForget the AI predictions. Look at the incomeAI predictions are everywhere, but Tim Plaehn is focused on something concrete: income. He's found a small ...Investors Alley | SponsoredFinally… options made simpleIan Cooper once believed successful options trading meant endless chart-watching, complex strategies, and big ...TradeWins | SponsoredElon says the ‘S’ wordElon Musk and Sam Altman have sued each other and feuded for years. Yet within days of one another, both men d...Paradigm Press | SponsoredThe chip inside every TeslaEvery Tesla built since 2012 pays this small, overlooked supplier a fee for its technology. So does every Star...Behind the Markets | SponsoredElon Musk’s One Stock Retirement PlanStanley Druckenmiller once said you don't get rich diversifying into 50 mediocre assets - you get rich finding...Brownstone Research | Sponsored80 Days Until America's Rare Earth Supply Chain ShiftChina controls more than 90% of global rare earth alloy production, leverage it is using to restrict exports t...The Tomorrow Investor | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oncobiologics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Oncobiologics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
